CY1106843T1 - Αναστολεις της κυτταρικης συγκολλησης που επηρεαζεται απο την alβ2 - Google Patents
Αναστολεις της κυτταρικης συγκολλησης που επηρεαζεται απο την alβ2Info
- Publication number
- CY1106843T1 CY1106843T1 CY20071101143T CY071101143T CY1106843T1 CY 1106843 T1 CY1106843 T1 CY 1106843T1 CY 20071101143 T CY20071101143 T CY 20071101143T CY 071101143 T CY071101143 T CY 071101143T CY 1106843 T1 CY1106843 T1 CY 1106843T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cell adhesion
- inhibitors
- alb2
- induced cell
- αlβ2
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μικρά μόρια σύμφωνα με τον τύπο (Ι) τα οποία είναι ισχυροί αναστολείς της επηρεαζόμενης από αLβ2 κυτταρικής συγκόλλησης και τα οποία θα μπορούν να είναι χρήσιμα για τη θεραπεία φλεγμονωδών νόσων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20796800P | 2000-05-31 | 2000-05-31 | |
PCT/US2001/012323 WO2001092253A2 (en) | 2000-05-31 | 2001-04-17 | Inhibitors of alpha l beta 2 mediated cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106843T1 true CY1106843T1 (el) | 2012-05-23 |
Family
ID=22772705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101143T CY1106843T1 (el) | 2000-05-31 | 2007-09-04 | Αναστολεις της κυτταρικης συγκολλησης που επηρεαζεται απο την alβ2 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6699888B2 (el) |
EP (1) | EP1284973B1 (el) |
JP (1) | JP3924531B2 (el) |
KR (1) | KR100527290B1 (el) |
CN (1) | CN1209358C (el) |
AT (1) | ATE365729T1 (el) |
AU (2) | AU2001253538B2 (el) |
BR (1) | BR0111188A (el) |
CA (1) | CA2411671C (el) |
CY (1) | CY1106843T1 (el) |
DE (1) | DE60129132T2 (el) |
DK (1) | DK1284973T3 (el) |
ES (1) | ES2284641T3 (el) |
HK (1) | HK1051370A1 (el) |
IL (1) | IL152961A0 (el) |
MX (1) | MXPA02011858A (el) |
NZ (1) | NZ522852A (el) |
PT (1) | PT1284973E (el) |
WO (1) | WO2001092253A2 (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101011373B1 (ko) | 2002-07-11 | 2011-01-28 | 비큐론 파마슈티컬스 인코포레이티드 | 항균작용을 갖는 n-히드록시아미드 유도체 |
FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US7354933B2 (en) | 2003-01-31 | 2008-04-08 | Aventis Pharma Sa | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US20090042901A1 (en) * | 2005-02-02 | 2009-02-12 | Kowa Co., Ltd. | Agent for prevention/therapy of disease caused by keratinocyte growth |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
AU2012241184B2 (en) * | 2006-03-27 | 2016-01-07 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
DK2656842T3 (en) | 2006-03-27 | 2016-11-07 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
AU2016201061B2 (en) * | 2006-03-27 | 2017-03-02 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
AU2013205325B2 (en) * | 2006-03-27 | 2016-03-24 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
CA2648139A1 (en) * | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders |
EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
SG10201402250TA (en) | 2009-05-12 | 2014-07-30 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
KR101972719B1 (ko) | 2010-02-16 | 2019-04-25 | 아라곤 파마슈티컬스, 인코포레이티드 | 안드로겐 수용체 조절제 및 이의 용도 |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
SG11202003402QA (en) | 2017-10-16 | 2020-05-28 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091596B1 (de) | 1982-04-08 | 1991-09-11 | Shell Internationale Researchmaatschappij B.V. | Neue Hydantoine, ihre Herstellung und Verwendung |
DE19540027A1 (de) | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
WO2001007048A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
-
2001
- 2001-04-17 CN CNB018104630A patent/CN1209358C/zh not_active Expired - Fee Related
- 2001-04-17 EP EP01927050A patent/EP1284973B1/en not_active Expired - Lifetime
- 2001-04-17 US US10/296,907 patent/US6699888B2/en not_active Expired - Fee Related
- 2001-04-17 DE DE60129132T patent/DE60129132T2/de not_active Expired - Fee Related
- 2001-04-17 AT AT01927050T patent/ATE365729T1/de not_active IP Right Cessation
- 2001-04-17 WO PCT/US2001/012323 patent/WO2001092253A2/en active IP Right Grant
- 2001-04-17 CA CA002411671A patent/CA2411671C/en not_active Expired - Fee Related
- 2001-04-17 ES ES01927050T patent/ES2284641T3/es not_active Expired - Lifetime
- 2001-04-17 MX MXPA02011858A patent/MXPA02011858A/es active IP Right Grant
- 2001-04-17 PT PT01927050T patent/PT1284973E/pt unknown
- 2001-04-17 AU AU2001253538A patent/AU2001253538B2/en not_active Ceased
- 2001-04-17 NZ NZ522852A patent/NZ522852A/en unknown
- 2001-04-17 KR KR10-2002-7014945A patent/KR100527290B1/ko not_active IP Right Cessation
- 2001-04-17 IL IL15296101A patent/IL152961A0/xx unknown
- 2001-04-17 JP JP2002500866A patent/JP3924531B2/ja not_active Expired - Fee Related
- 2001-04-17 BR BR0111188-4A patent/BR0111188A/pt not_active IP Right Cessation
- 2001-04-17 DK DK01927050T patent/DK1284973T3/da active
- 2001-04-17 AU AU5353801A patent/AU5353801A/xx active Pending
-
2003
- 2003-05-23 HK HK03103658A patent/HK1051370A1/xx not_active IP Right Cessation
-
2007
- 2007-09-04 CY CY20071101143T patent/CY1106843T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2001253538B2 (en) | 2004-03-04 |
KR100527290B1 (ko) | 2005-11-09 |
JP3924531B2 (ja) | 2007-06-06 |
IL152961A0 (en) | 2003-06-24 |
HK1051370A1 (en) | 2003-08-01 |
DK1284973T3 (da) | 2007-10-08 |
NZ522852A (en) | 2004-09-24 |
WO2001092253A2 (en) | 2001-12-06 |
US20030225138A1 (en) | 2003-12-04 |
KR20030015235A (ko) | 2003-02-20 |
MXPA02011858A (es) | 2004-07-30 |
EP1284973A2 (en) | 2003-02-26 |
CN1209358C (zh) | 2005-07-06 |
DE60129132T2 (de) | 2008-02-28 |
CA2411671C (en) | 2007-06-05 |
WO2001092253A3 (en) | 2002-05-23 |
CA2411671A1 (en) | 2001-12-06 |
US6699888B2 (en) | 2004-03-02 |
BR0111188A (pt) | 2003-06-10 |
ES2284641T3 (es) | 2007-11-16 |
AU5353801A (en) | 2001-12-11 |
CN1432007A (zh) | 2003-07-23 |
ATE365729T1 (de) | 2007-07-15 |
DE60129132D1 (de) | 2007-08-09 |
JP2003535087A (ja) | 2003-11-25 |
PT1284973E (pt) | 2007-08-17 |
EP1284973B1 (en) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106843T1 (el) | Αναστολεις της κυτταρικης συγκολλησης που επηρεαζεται απο την alβ2 | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
CY1106598T1 (el) | Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα | |
CY1108407T1 (el) | Τριαμιδο-υποκατεστημενες ινδολες, βενζοφουρανια και βενζοθειοφαινεια ως αναστολεις της μικροσωμιακης πρωτεϊνης μεταφορας τριγλυκεριδιων (mtp) και/ή της εκκρισης απολιποπρωτεϊνης β (αρο β) | |
CY1117217T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης | |
NO20041493L (no) | Kjemiske forbindelser. | |
CY1112938T1 (el) | Παραγωγα n-φαινυλ-2-πυριμιδινης-αμινης | |
CY1110214T1 (el) | Μεθοδοι και ενδιαμεσα | |
IS7258A (is) | Arýloxýfenýl og arýlsúlfanýlfenýl afleiður | |
CY1113651T1 (el) | Αντιφλεγμονωδη σκευασματα | |
CY1109309T1 (el) | Παραγωγα γλυκοπυρανοσυλοξυπυραζολης και χρηση αυτων σε φαρμακευτικα σκευασματα | |
IS7220A (is) | Latar af þætti XA og öðrum rað-próteösum sem tengjast storknunar keðjuverkun | |
CY1106894T1 (el) | Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων | |
CY1108722T1 (el) | Πολυκυκλικες ενωσεις και η χρηση τους ως αναστολεων των ενζυμων parp, vegfr2 και mlk3 | |
CY1113515T1 (el) | Παραγωγα πυραζολιου για αντιμετωπιση ηiv | |
EA200401157A1 (ru) | N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv | |
NO20081636L (no) | FAP - inhibitorer | |
CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
CY1112085T1 (el) | Παραγωγα κυκλοεξυλαμινης ισοκινολονης ως αναστολεις της rho-κινασης | |
TR200103787T1 (tr) | Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler | |
CY1105097T1 (el) | Χρηση παραγωγων ν-φαινυλο-2-πυριμιδιναμινης στην αγωγη εναντι φλεγμονωδων ασθενειων | |
CY1109838T1 (el) | Μεθοδος δια παρασκευη 3-ο-προστατευμενων μορφινονων και καρβοξυλικων αλατων διενολης 3-ο-προστατευμενης μορφινονης | |
NO20043016L (no) | 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav | |
CY1107156T1 (el) | Νεα μεθοδος συνθεσης του (7-μεθοξυ-3,4-διυδρο-1-ναφθαλινυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης | |
NO20051146L (no) | Fremgangsmate for fremstilling av mellomprodukter nyttige for fremstilling av tubulininhibitorer |